Comparative efficacy and safety of chimeric and recombinant anti-TNF-α mAbs
TNF-α has been known since 1985. It is a multifunctional proinflammatory cytokine, synthesized mainly by monocytes and macrophages. Since its discovery, many studies have been conducted that have proven that it provides homeostatic function and regulates many biological processes in the body. Violat...
Main Authors: | V. N. Drozdov, E. V. Shikh, A. A. Astapovskiy, S. Yu. Serebrova, A. K. Starodubtsev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-05-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/6179 |
Similar Items
-
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
by: Heejin Lim, et al.
Published: (2018-03-01) -
Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
by: Laine J, et al.
Published: (2016-04-01) -
EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY
by: A. S. Avdeeva, et al.
Published: (2014-12-01) -
Crohn's Disease: General characteristics and treatment with Adalimumabe biopharmaceutical
by: S. A. Marques, et al.
Published: (2018-02-01) -
CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)